在模拟纤维化微环境的离体组织模型中,子宫内膜异位组织碎片经冷冻保存后仍保持活性
本研究从28例患者手术切除获取三种亚型子宫内膜异位组织碎片,经三种方案冷冻保存后 thawing 并培养,评估活性和代谢活性,并与11例新鲜碎片比较;冷冻后碎片活性保持,可用于离体干预实验检测吡非尼酮或二甲双胍对纤维化标志物表达的影响。
要点
- 冷冻保存后 thawing 的子宫内膜异位组织碎片在培养至少3天内仍保持活性。
- 冷冻后代谢活性与新鲜组织碎片相当,腹膜型相对活性70%、卵巢型43%、深部型94%。
- 该离体模型可用于检测抗纤维化干预,如吡非尼酮或二甲双胍对COL1A1和CEMIP表达的影响。
核心结论
- 冷冻保存的子宫内膜异位组织碎片 thawing 后仍保持活性,至少可培养3天,可用于建立离体子宫内膜异位模型以高效测试潜在治疗药物。
研究设计与样本
- 研究获取28例患者三种亚型子宫内膜异位组织碎片(n=45),按三种方案冷冻保存,thawing 后培养24小时评估活性和代谢活性。
- 活性与11例新鲜手术切除碎片直接比较;另用2例患者冷冻 thawing 碎片进行72小时吡非尼酮或二甲双胍干预实验。
主要发现
- 腹膜型(PER)、卵巢型(OMA)和深部型(DE)病灶碎片在二甲基亚砜培养基中冷冻保存后代谢活性保持良好,与新鲜组织碎片相当。
- 相对新鲜组织的代谢活性:PER为70%(CI: 92-47%),OMA为43%(CI: 53-15%),DE为94%(CI: 186-3%)。
- 冷冻 thawing 后培养24小时,PER病灶碎片细胞活性为92%(CI: 87-96%),OMA为95%(CI: 91-98%),DE为88%(CI: 78-98%)。
- 吡非尼酮或二甲双胍处理72小时后,全组织碎片和分离的肌成纤维细胞中纤维化标志物COL1A1和CEMIP基因表达差异可被检测到。
局限性
- 子宫内膜异位组织碎片的活性和代谢活性可能因手术过程中受到的损伤而部分受损,导致样本间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is it possible to establish an ex vivo endometriosis model using cryopreserved endometriotic tissue fragments? SUMMARY ANSWER: Cryopreserved endometriotic tissue fragments remain viable after thawing and during at least 3 days of culture and can therefore be used to establish an ex vivo endometriosis model to efficiently test potential therapeutic agents. WHAT IS KNOWN ALREADY: Endometriosis is the most prevalent benign gynecologic disease with an enormous societal burden; however, curative therapies are still lacking. To efficiently test potential new therapies, an ex vivo model based on previously cryopreserved endometriotic tissue that recapitulates the different endometriosis subtypes and their microenvironment is highly desirable. STUDY DESIGN, SIZE, DURATION: Endometriotic tissue fragments of three different subtypes were obtained from 28 patients by surgical resection. After cryopreservation and thawing, viability and metabolic activity of these tissue fragments were assessed. Viability was compared with fresh fragments from 11 patients directly after surgical removal. Experimental intervention studies were performed in cryopreserved and thawed tissue fragments from two patients to confirm the usability of these tissues for ex vivo intervention studies. PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometriotic tissue fragments (n = 45) were cryopreserved according to three different protocols. After thawing, fragments were cultured for 24 h. A resazurin-based assay was performed to assess the metabolic activity of the tissue fragments. In addition, cell type-specific viability was analyzed by VivaFix, Hoechst 33342, and α-smooth muscle actin immunofluorescence staining and confocal microscopy. The presence of endometriosis was histologically confirmed based on hematoxylin-eosin staining. Cryopreserved and thawed tissue fragments were treated for 72 h with pirfenidone or metformin and COL1A1 and CEMIP gene expressions were assessed using RT-PCR and RT-qPCR, either in the whole tissue fragments or in myofibroblasts isolated by laser capture microdissection. MAIN RESULTS AND THE ROLE OF CHANCE: Metabolic activity of endometriotic tissue fragments obtained from peritoneal (PER), ovarian (OMA), and deep (DE) endometriotic lesions was well preserved after cryopreservation in a dimethyl sulfoxide-based medium and was comparable with fresh tissue fragments. Relative metabolic activity compared to fresh tissue was 70% (CI: 92-47%) in PER, 43% (CI: 53-15%) in OMA and 94% (CI: 186-3%) in DE lesions. In fragments from PE lesions 92% (CI: 87-96%), from OMA lesions 95% (CI: 91-98%), and from DE lesions 88% (CI: 78-98%) of cells were viable after cryopreservation and thawing followed by a 24-h culture period. Differences in gene expression of fibrotic markers COL1A1 and CEMIP after 72-h treatment with pirfenidone or metformin could be detected in whole tissue fragments and in isolated myofibroblasts, indicating that cryopreserved and thawed endometriotic tissue fragments are suitable for testing anti-fibrotic interventions. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Viability and metabolic activity of the endometriotic tissue fragments may have been partially compromised by damage sustained during the surgical procedure, contributing to inter-sample variance. WIDER IMPLICATIONS OF THE FINDINGS: The storage of viable endometriotic tissue fragments for later usage in an ex vivo model creates the possibility to efficiently test potential new therapeutic strategies and facilitates the exchange of viable endometriotic tissue between different research laboratories. STUDY FUNDING/COMPETING INTEREST(S): This study was not financially supported by external funding. The authors declare no competing interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Vissers G, Peek R, Verdurmen WPR, et al. Endometriotic tissue fragments are viable after cryopreservation in an ex vivo tissue model recapitulating the fibrotic microenvironment. Hum Reprod. 2024. PMID: 39025483. doi:10.1093/humrep/deae164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。